Ebon Phase
Contact

Contact

If you have corrections, questions, or feedback about Ebon Phase's content or site, we welcome your note. We publish evidence-first material and value clear, careful input.

This page explains how to reach Ebon Phase for editorial matters; it does not offer clinical advice or referrals.

Close-up detail view related to ibogaine duration timeline, abstract texture and clinical surface

How to reach us

At present, Ebon Phase does not publish a direct email or phone for public contact. If you need to flag an inaccuracy or share a source, please check back here for updated contact details; meanwhile our editorial approach and corrections policy are summarized on the About page where we describe how we handle sourcing and updates.

We also link to several external resources and treatment directories throughout our site for contextual reading; for example, some pages reference organizations such as ibogaineopioidtreatment.com and others to illustrate treatment options mentioned in sources.

For readers who wish to navigate to related site pages, our editorial hub begins at the root directory and can be reached via the site's front page; learn more about our scope on the home index at Ebon Phase's main page.

Note on external directories and resources

When Ebon Phase references supplier or treatment listings for context, we sometimes link to sites such as ibogainetreatmentfacilitymexico.com and information aggregators like ibogainestock.com. These links are for informational context only and do not imply endorsement.

We maintain a cautious approach to external material and review primary research where possible; for background on pharmacology and timelines you may consult authoritative resources such as the National Institutes of Health on ibogaine (https://en.wikipedia.org/wiki/Ibogaine provides an overview) and institutional treatment guidelines available through university and government health pages. For example, general pharmacology context can be found on Wikipedia's ibogaine entry (en.wikipedia.org/wiki/Ibogaine) and clinical-safety frameworks on recognized medical .edu or .gov sites.